The multiple effects GLP-1RAs have on obesity and ASCVD—a reflection of the multisystemic roles of GLP-1 receptor functions in the setting of diabetes and OSA—can potentially lead to a reduction of polypharmacy and cost, amelioration of OSA-related cardiometabolic derangements, and enhancement of OSA-related quality of life indicators [19,25,45,46,47,48,49,50,51,52,53]. The gene discussed is GLP1R; the disease is Obesity.